Select a Region
North America

Browsing Archive: Nervous SystemNervous System | EVERSANA

EVERSANA
Posted on 9 月 20, 20239/20/23

Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada

EVERSANA
Posted on 9 月 20, 20239/20/23

Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis

EVERSANA
Posted on 2 月 1, 20232/1/23

Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain

EVERSANA
Posted on 2 月 1, 20232/1/23

Efficacy classification of modern therapies in multiple sclerosis

EVERSANA
Posted on 2 月 1, 20232/1/23

Network Meta-analysis of Disease-modifying Therapies for Relapsing Multiple Sclerosis Based on Confirmed Disability Progression: Investigating the Influence of Cross-trial Differences in Endpoint Definition

EVERSANA
Posted on 2 月 1, 20232/1/23

Relapse Reduction by Disease-modifying Therapies for Relapsing Multiple Sclerosis: A Network Meta-analysis

EVERSANA
Posted on 2 月 1, 20232/1/23

Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses

EVERSANA
Posted on 2 月 1, 20232/1/23

Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis

EVERSANA
Posted on 2 月 1, 20232/1/23

A systematic review and network meta‐analysis comparing ofatumumab with other disease‐modifying therapies available in Japan for the treatment of patients with relapsing multiple sclerosis

EVERSANA
Posted on 1 月 25, 20231/25/23

Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada.

Nervous System